Turbine

27/01/2026

Dual-payload ADCs won’t reach their full potential if they are designed by trial and error 🧪

Even as ADC pipelines are growing at record pace, tumor heterogeneity, resistance, and off-tumor toxicity remain major hurdles that often stand in the way of deeper and more durable clinical responses. Dual-payload ADCs are building a growing body of evidence showing how carefully combined cytotoxic mechanisms can help reach more tumor cells, slow the emergence of resistance, and move toward treatments that are both safer and more effective, ultimately offering more lasting relief for patients.

In this article, Jerzy Woźnicki, PhD discusses how Turbine’s Virtual Lab and in silico disease models can be used to screen and stress-test dual-payload combinations before they ever reach the bench, and how this approach helps uncover where the mechanisms behind true synergy and resistance are most likely to emerge. 🔬🖥️

Read the full article here 👇

Dual-payload ADCs are gaining traction, offering opportunities to overcome the tumour heterogeneity and resistance challenges faced by conventional ADCs.

20/01/2026

200+ live yesterday! 🚀

A huge thank you to everyone who joined our Virtual Biology Community Meetup. We couldn’t have asked for a better crowd to start our series.

The kick-off was all about the "first year of the virtual cell", discussing the challenge of virtualizing biological experiments and the road ahead for R&D.

Missed it or want to rewatch? Catch the full replay here: https://eu1.hubs.ly/H0r5gz20

This was just the first session. Keep your eyes peeled for more deep dives coming later this year, and follow our channels to stay updated:

🔹 X (Twitter): https://eu1.hubs.ly/H0r5fgG0
🔹 Bluesky: https://eu1.hubs.ly/H0r5c8B0
🔹 YouTube: https://eu1.hubs.ly/H0r5gBV0

​The past year marked a turning point for virtual biology and virtual cell modeling. After years of promises, bold claims, and accelerating hype, 2025 was th...

13/01/2026

🎉 The speaker lineup is complete!

Join us on January 19 for the Virtual Biology Community Meetup, a community-powered online event exploring where virtual cells and computational biology are heading in 2026.

We’re excited to welcome Fabian Theis, Director of the Institute of Computational Biology and Professor at TUM Mathematics and Life Sciences; Ron Alfa, MD, PhD, Co-founder & CEO at NOETIK; and Amaro Taylor-Weiner, PhD, former Chief AI Officer at Absci and Biotech Co-founder - moderated by Daniel Veres, MD, PhD, Co-founder & CSO at Turbine.

📅 Jan 19, 2026 | 4:30-6:00 PM CET
🌐 Online
👉 Register via Luma: https://eu1.hubs.ly/H0qXq-20

If you’re curious about the future of virtual biology, this is a great way to start the year after a busy JPM Week. 🚀

09/01/2026

High benchmark scores don’t mean your virtual cell is useful.

Impressive metrics often fail to translate into reliable biological insight to help decision-making. Benchmarks focused on limited real-world impact, weak or missing domain baselines, growing risks of data leakage, and overly convenient metrics can all create a false sense of progress.

In this post, our CTO and Gerold Csendes shares how we assess the actual utility of virtual cells in practice and why evaluation rigor, not leaderboard position, ultimately determines whether a model is worth trusting.

Read our note - Assessing a Virtual Cell’s Utility: https://eu1.hubs.ly/H0qQZ7T0
Substack version: https://eu1.hubs.ly/H0qQZNd0

05/01/2026

🚀 Turbine @ JPM Week – we’re heading to San Francisco!

JPM Week is coming up and our calendar is filling fast: plenty of meetings, great conversations, and strong momentum ahead.

You’ll find Szabolcs Nagy (CEO & Co-founder), Daniel Veres MD PhD (CSO & Co-founder), Louisa Roberts (CBO), Luca Bárdió (PR & Storytelling) and Neeraj Rao (Business Development Director) on site throughout the week.

We’re also kicking off the week with our Wake Up with Turbine morning event and it's great to see such strong interest from the community.

If you’re in San Francisco during JPM and would like to connect, feel free to reach out.

📍 San Francisco | JPM Week
🔗 Event details (act fast, we're at 99% capacity): https://eu1.hubs.ly/H0qJhS10

19/12/2025

🇭🇺 Csapatunk is felöltötte ma a "csúnya" karácsonyi pulcsikat, hogy csatlakozzunk a Gyermekgyógyítók által szervezett inspiráló és fontos kezdeményezéshez.

A cél, hogy daganatos gyermekek gyógyulását segítsük, többek között hozzájárulva modern orvosi felszerelések beszerzéséhez.

Ti is hozzájárulhattok a munkájukhoz 500 Ft-tal, ha sms-ben elkülditek a 49-es kódot a 13600-as számra, és töltötök fel egy képet facebookra vagy instagramra a hashtaggel.

További részletek:
https://www.facebook.com/events/1690704852084704

🇺🇸 Our team is finally wearing their "ugly" Christmas sweaters today, to help an inspirational event and a good cause organised by ChildCarers (Gyermekgyógyítók) Foundation.

The goal is for child cancer patients to heal under decent conditions by helping doctors and nurses receive modern medical equipment.

You can also send an SMS to their care-number 13600 to support their work with 500 HUF (send code "49") and upload a picture to facebook or instagram with the hashtag ( )

Further details:
https://www.facebook.com/events/1690704852084704

18/12/2025

🎄 Before switching fully into holiday mode, here’s a quick JPM week reminder:

Wake Up with Turbine @ JPM
January 13 | 7:00-11:00 AM
Bluestone Lane Front Street Coffee Shop

Coffee, casual conversations, and a Virtual Biology Q&A (from 7:00 to 8:00 AM) with Szabolcs Nagy (CEO & Co-founder), Daniel Veres, MD PhD (CSO & Co-founder), and Louisa Roberts (CBO).

Drop by anytime to meet the team and see the Virtual Lab Station in action.

🎁 Possibly the best way to start your JPM morning.
👉 Details & RSVP: https://eu1.hubs.ly/H0qxqNy0

03/12/2025

Wake up with Turbine @ JPM

We’re taking over a Bluestone Lane café during JPM and kicking off the morning Turbine-style. Join us for Wake Up with Turbine - a casual morning session with coffee and a Virtual Biology Q&A with Szabolcs Nagy, CEO & Co-founder, Daniel Veres, CSO & Co-founder and Louisa Roberts, CBO from 7-8 AM. After that, the space stays open until 11 AM, so drop by anytime to meet the team, grab a coffee, and check out the Virtual Lab Station in action.

Honestly, it might just be the best way to start your January 13 morning.

Find all the details here & RSVP: https://eu1.hubs.ly/H0q7JsW0

24/11/2025

What happens when a scientist steps into the future of experimentation and becomes a VIRTUAL LAB SUPERUSER?

Meet Iván Fekete, Turbine Co-founder and translational biologist, using the Virtual Lab every single day to understand disease biology at a depth and speed that traditional workflows simply can’t match. Tune in on the debut episode of our Superuser series as he tackles a major question: How to combine ADC payloads to achieve synergy?

In under 5 minutes, you’ll see how the Virtual Lab empowers Iván to:
🔹simulate a myriad of virtual experiments in seconds
🔹reveal combination synergy and resistance patterns
🔹investigate the mechanisms driving cellular response on a single platform

No coding. No friction. Just intuitive in-silico experimentation that lets any scientist test all their ideas before wet lab validation. And beyond this episode, the Virtual Lab also helps researchers walk into the wet lab with sharper, more strategic plans - enhancing clinical translatability and supporting more rational decisions.

Iván uses it every day - and you could too, without needing an entire data-science team. Our virtual biology platform is a practical product already integrated into pharma R&D workflows.

Ready to become a superuser? 🚀

https://eu1.hubs.ly/H0pWNf-0

Let’s learn more about our ADC Simulation Suite here: https://eu1.hubs.ly/H0pWNd80

Meet Iván Fekete, Turbine Co-founder and translational biologist, using the Virtual Lab every single day to understand disease biology at a depth and speed t...

21/11/2025

🔥We made the Sifted Future 50 ranking!

Sifted has named us one of Europe’s rising startups showing exceptional revenue growth in their latest financial year, putting us on track to qualify for the Sifted 250 in 2026.

Scaling is tough, but with an incredible team and supportive partners, we’re building real momentum and this is just the beginning. 🚀

Some seriously impressive startups made the list, see who’s alongside us!

20/11/2025

🤖We’re heading to AI for health Summit 2025, where our Co-founder & CEO, Szabolcs Nagy, will join the panel:

“Boosting Drug Discovery with Agents & Digital Twins”
November 26, 2025 | 12:15-12:45 PM

The session will bring together leading voices shaping the future of AI-powered drug discovery, including experts from Bioptimus, EY, EPFL, and Eli Lilly to explore how virtual cells and digital twins can transform pharma R&D.

At Turbine, we’re virtualizing biological experiments with AI to accelerate discovery and improve clinical translatability.

If you’re attending and want to explore collaboration opportunities or learn more about our approach, feel free to reach out to our team: Pier Giorgio, Luca Bárdió, and Szabolcs Nagy.

See you in Paris!🥐

19/11/2025

So… what is a virtual cell?
In its ideal form, a virtual cell would be a complete, general simulation of biology - one that can accurately predict outcomes in entirely new contexts without retraining.

💡This is the dream. And it’s not something we have today and that’s perfectly okay.
Yet over the past year, virtual cells have become one of the most hyped topics in biotech and AI. And as with any hype cycle, the noise often makes it hard to see what the technology can really do today and what it can’t.

What we have today are narrow virtual cell models that can predict outcomes within a well-defined assay, where we have sufficient calibration data. These are already virtualizing many experiments with impressive accuracy (through what we call virtual assays).

At Turbine we already have a ready-to-use, practical product built on this principle, one that pharma teams are already integrating directly into their workflows.

👉Read our Founder & CTO Kristof Szalay's blog post for the deeper explanation here:

and what they can't - because the bottleneck is not computing power